Oxford BioDynamics to provide tests to largest UK charitable hospital
(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.
Read moreWed, 22nd Aug 2018 08:39
(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - Oxford BioDynamics PLC said on Wednesday that it has opened a clinical testing laboratory in the UK to perform EpiSwitch prostate screening tests.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more(Correcting headline to show loss widened, revenue rose)
Read more(Correcting headline to show profit and revenue rose)
Read more(Alliance News) - Oxford BioDynamics PLC on Wednesday said its full-year loss narrowed, but saw its revenue jump on contracts for EpiSwitch.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more(Sharecast News) - Oxford Biodynamics revealed on Friday that Vulpes Testudo Fund had offloaded 777,000 ordinary shares in the AIM-listed biotechnology company.
Read moreOxford BioDynamics PLC - biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform - Reports that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle has sold 777,000 shares of one pence each at an average price of 38.3p each. Diggle is now interested in 27.6 million shares in total, through the Vulpes Testudo and Vulpes Life Sciences Funds. These represent approximately 13.62% of Oxford BioDynamics's current issued share capital. Company's market capitalisation is GBP69.79 million.
Read more(Alliance News) - Oxford BioDynamics PLC shares surged on Wednesday as it announced a strategic deal with Bupa UK Insurance to enhance access to a "first-of-its-kind" blood test for cancer patients.
Read more(Sharecast News) - Precision test developer Oxford BioDynamics has successfully secured a proprietary laboratory analysis (PLA) code from the American Medical Association's (AMA) Current Procedural Terminology (CPT) Editorial Board, it announced on Tuesday.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read more(Alliance News) - Oxford BioDynamics PLC on Tuesday said it has been issued an insurance reimbursement code for its EpiSwitch product from the American Medical Association.
Read more